Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

IF 6.1 2区 医学 Q1 ONCOLOGY Cancer Pub Date : 2024-12-01 DOI:10.1002/cncr.35612
Alan H. Bryce MD, Neeraj Agarwal MD, Himisha Beltran MD, Maha H. Hussain MD, Oliver Sartor MD, Neal Shore MD, Emmanuel S. Antonarakis MD, Andrew J. Armstrong MD, MSc, Jeremie Calais MD, PhD, Michael A. Carducci MD, Tanya Barauskas Dorff MD, Jason A. Efstathiou MD, DPhil, Martin Gleave MD, Leonard G. Gomella MD, Celestia Higano MD, Thomas A. Hope MD, Andrei Iagaru MD, Alicia K. Morgans MD, MPH, David S. Morris MD, Michael J. Morris MD, Daniel P. Petrylak MD, Robert E. Reiter MD, Matthew B. Rettig MD, MBA, Charles J. Ryan MD, Scott B. Sellinger MD, Daniel E. Spratt MD, Sandy Srinivas MD, Scott T. Tagawa MD, MS, Mary-Ellen Taplin MD, Evan Y. Yu MD, Tian Zhang MD, Rana R. McKay MD, Phillip J. Koo MD, E. David Crawford MD
{"title":"Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024","authors":"Alan H. Bryce MD,&nbsp;Neeraj Agarwal MD,&nbsp;Himisha Beltran MD,&nbsp;Maha H. Hussain MD,&nbsp;Oliver Sartor MD,&nbsp;Neal Shore MD,&nbsp;Emmanuel S. Antonarakis MD,&nbsp;Andrew J. Armstrong MD, MSc,&nbsp;Jeremie Calais MD, PhD,&nbsp;Michael A. Carducci MD,&nbsp;Tanya Barauskas Dorff MD,&nbsp;Jason A. Efstathiou MD, DPhil,&nbsp;Martin Gleave MD,&nbsp;Leonard G. Gomella MD,&nbsp;Celestia Higano MD,&nbsp;Thomas A. Hope MD,&nbsp;Andrei Iagaru MD,&nbsp;Alicia K. Morgans MD, MPH,&nbsp;David S. Morris MD,&nbsp;Michael J. Morris MD,&nbsp;Daniel P. Petrylak MD,&nbsp;Robert E. Reiter MD,&nbsp;Matthew B. Rettig MD, MBA,&nbsp;Charles J. Ryan MD,&nbsp;Scott B. Sellinger MD,&nbsp;Daniel E. Spratt MD,&nbsp;Sandy Srinivas MD,&nbsp;Scott T. Tagawa MD, MS,&nbsp;Mary-Ellen Taplin MD,&nbsp;Evan Y. Yu MD,&nbsp;Tian Zhang MD,&nbsp;Rana R. McKay MD,&nbsp;Phillip J. Koo MD,&nbsp;E. David Crawford MD","doi":"10.1002/cncr.35612","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694557/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35612","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对生化复发和晚期前列腺癌患者实施循证策略:2024年美国前列腺癌会议的共识建议
目前美国晚期前列腺癌管理的临床实践指南包含基于随机对照试验的高水平证据的建议;然而,这些指南并没有解决那些在前瞻性试验中没有得到回答,但在日常实践中却遇到的微妙的临床问题。为了解决这些实际问题,2024年美国前列腺癌会议(USPCC 2024)的成立旨在为缺乏1级证据的情况提供以美国为重点的专家临床决策指导。在第二届USPCC年度会议(USPCC 2024)上,一个多学科专家小组召开会议,讨论与5个主题领域相关的持续临床挑战:生化复发;转移性、去势抵抗性前列腺癌;聚[adp -核糖]聚合酶抑制剂;前列腺特异性膜抗原放射配体治疗;以及转移性、去势抵抗性前列腺癌。通过改进的德尔菲过程,制定了34项共识建议,旨在为管理前列腺癌的临床医生提供与实施新治疗和技术相关的指导。在本报告中,作者回顾了USPCC 2024专家确定的共识领域,并评估了当前临床证据转化应用方面尚未满足的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
期刊最新文献
The relationship between cardiometabolic abnormalities and mortality in the Women’s Health Initiative: A comparison of associations among women with cancer to women without cancer Caring for caregivers in early-phase clinical oncology trials The missing data: A review of gender and sex disparities in research The human oral microbiome and risk of colorectal cancer within three prospective cohort studies in the United States Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1